TITLE:
Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

CONDITION:
HIV Infections

INTERVENTION:
Thymopentin

SUMMARY:

      Examine the ability of thymopentin (Timunox) to:

      Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter
      the clinical findings in patients infected with HIV who do not yet have AIDS.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine.

        Prior Medication:

        Allowed:

          -  Aerosolized pentamidine.

        Exclusion Criteria

        Co-existing Condition:

        Patients with an abnormal chest x-ray indicative of active disease (opportunistic
        infection) within 30 days prior to entry are excluded.

        Concurrent Medication:

        Excluded within 90 days of study entry:

          -  Zidovudine (AZT).

        Prior Medication:

        Excluded within 30 days of study entry:

          -  Immunomodulatory or experimental therapy.

          -  Excluded within 90 days of study entry:

          -  Zidovudine (AZT).

        Patients must not have:

          -  Hemophilia A or B or other hematologic disorders requiring current or previous
             administration of blood products.

          -  AIDS as defined by the CDC (except for those with HIV "wasting syndrome").

          -  Significant hepatic disease.

          -  Thrombocytopenia (< 75000 platelets/mm3).

        Patient must voluntarily sign consent and be seropositive for HIV-1 (ELISA assay)
        confirmed by Western blot.

          -  HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of
             patient's peripheral blood monocytes (PBMC) on two separate occasions.

          -  Patients with HIV "wasting syndrome" are included.

        Intravenous drug abuse.
      
